Lupin recalling antibiotic produced at plant cited by FDA

Multiple syringes

India’s Lupin is recalling nearly 54,000 vials of an antibiotic made at its plant in Mandideep, India. It turns out that it is one of the facilities to receive citations during an inspection this year by the FDA.

According to the most recent FDA Enforcement Report, Lupin is recalling 53,902 vials of injected ceftriaxone because the drug was manufactured using active pharmaceutical ingredients whose intermediates failed specifications. The recall actually began in March but was just posted by the FDA after being deemed a Class III. 

In March, Lupin reported in a filing with the Bombay Stock Exchange that it had received four observations for two plants at its Mandideep site following a two-week inspection by the FDA in February. Lupin, who referred to the citations as "minor in nature," said one of the observations had to do with the use of a "non-conforming" intermediate.  

Lupin last year also received a Form 483 with 9 observations for a plant in Goa, and the year before the FDA cited a facility in Indore with half a dozen.

Lupin, which claims to be one of the fastest-growing generics companies selling in the U.S., earlier this year completed a $900 million deal to buy New Jersey-based Gavis Pharmaceuticals. Lupin picked up in the deal a 45,000-square-foot manufacturing and R&D site and a 124,000-square-foot packaging and distribution operation in Somerset, NJ. It also got a portfolio of 120 marketed products and 62 ANDA filings.

Conference

The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

- access the recalls here 

Related Articles: 
FDA cites Lupin Indian facilities for what drugmaker calls 'minor' issues 
Lupin gets first U.S. manufacturing base with buyout of GAVIS

Suggested Articles

The FDA lambasted Strides Pharma in a warning letter after inspectors found testing records in the trash and in bags by a shredder.

Chinese biotech CMBG hopes to get a cell manufacturing facility built in nine months and more manufacturing news of note.

Kite has been buying the viral vector starting material for its CAR-T treatment Yescarta from contractors but says it is time to produce its own.